Next Article in Journal
Metabolic Profiling of Dendrobium officinale in Response to Precursors and Methyl Jasmonate
Previous Article in Journal
Functional Characterization of the Steroid Reductase Genes GmDET2a and GmDET2b from Glycine max
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2018, 19(3), 727; https://doi.org/10.3390/ijms19030727

EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension

1
Department of Respiratory Therapy, Chang-Gung University College of Medicine, Tao-Yuan 33353, Taiwan
2
Cardiovascular Division, Chang Gung Memorial Hospital, Tao-Yuan 33353, Taiwan
3
Department of Respiratory Care, Chang-Gung University of Science and Technology, Chia-Yi 61363, Taiwan
4
Respiratory Therapy and Chest Medicine, Cathay General Hospital, Taipei 10630, Taiwan
5
Division of Thoracic Medicine, Chang Gung Memorial Hospital, Tao-Yuan 33353, Taiwan
*
Author to whom correspondence should be addressed.
Received: 22 January 2018 / Revised: 16 February 2018 / Accepted: 1 March 2018 / Published: 3 March 2018
(This article belongs to the Special Issue Molecular Research on Pulmonary Hypertension)
View Full-Text   |   Download PDF [4134 KB, uploaded 3 March 2018]   |  

Abstract

Right ventricular (RV) hypertrophy is characterized by cardiac fibrosis due to endothelial–mesenchymal transition (EndMT) and increased collagen production in pulmonary arterial hypertension (PAH) patients, but the mechanisms for restoring RV function are unclear. Prostanoid agonists are effective vasodilators for PAH treatment that bind selective prostanoid receptors to modulate vascular dilation. The importance of prostanoid signaling in the RV is not clear. We investigated the effects of the EP4-specific agonist L-902,688 on cardiac fibrosis and TGF-β-induced EndMT. EP4-specific agonist treatment reduced right ventricle fibrosis in the monocrotaline (MCT)-induced PAH rat model. L-902,688 (1 µM) attenuated TGF-β-induced Twist and α-smooth muscle actin (α-SMA) expression, but these effects were reversed by AH23848 (an EP4 antagonist), highlighting the crucial role of EP4 in suppressing TGF-β-induced EndMT. These data indicate that the selective EP4 agonist L-902,688 attenuates RV fibrosis and suggest a potential approach to reducing RV fibrosis in patients with PAH. View Full-Text
Keywords: right ventricular fibrosis; EP4 agonist; EndMT right ventricular fibrosis; EP4 agonist; EndMT
Figures

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Lai, Y.-J.; Chen, I.-C.; Li, H.-H.; Huang, C.-C. EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension. Int. J. Mol. Sci. 2018, 19, 727.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top